Recent news on Retisert

Bausch & Lomb Announces New US Sales Organization Responsible for ...  -  May 17, 2007
PharmaLive.com (press release),This dedicated retina sales team will support the Millennium ™ Microsurgical System and associated products, Storz ® vitreoretinal instruments, Retisert

Alimera Sciences' Medidur(TM) Trial Exceeds 500 Patient Mark In ...  -  Apr 24, 2007
Medical News Today (press release),Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(R). pSivida has licensed the technologies underlying both of these products to Bausch & Lomb.

pSivida Sells AION Diagnostics Subsidiary  -  Apr 13, 2007
PharmaLive.com (press release),Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(R). pSivida has licensed the technologies underlying both of these products to Bausch & Lomb.

Bausch & Lomb Reports Preliminary and Unaudited Full-Year and ...  -  Mar 6, 2007
Business Wire (press release),Continued sales momentum for the Retisert® drug delivery implant. A return to more normalized growth levels for the Freda business in 2007,

pSivida Announcement: Retisert TM Drug Implant Receives Product ...  -  Jan 29, 2007
Business Wire (press release),The Retisert TM implant was approved as a single indication orphan drug by the United States Food and Drug Administration for the treatment of chronic

PSDV: Retisert(TM) Receives Product Bill Code for Medicare ...  -  Jan 29, 2007
Insurance News Net,...pSivida Limited (PSDV) announced that RetisertTM, developed jointly by pSivida and Bausch & Lomb (BOL), has been allocated a product specific J-Code by the

pSivida announces A$11.5m (US$9m) placement  -  Feb 19, 2007
dBusinessNews Boston (press release),...failure of the results of the Retisert™ for DME trial to be a good indicator of the results of pSivida’s ongoing Phase III Medidur™ for DME trial;

pSivida Announcement: RetisertTM Drug Implant Receives Product ...  -  Jan 29, 2007
dBusinessNews Boston (press release),Bausch & Lomb own the trademarks Vitrasert® and Retisert™. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb.

pSivida Limited (PSDV) Says RetisertTM Drug Implant Receives ...  -  Jan 29, 2007
StreetInsider.com (subscription),...pSivida Limited (NASDAQ: PSDV) announced that Retisert, developed jointly by pSivida and Bausch & Lomb (NYSE: BOL), has been allocated a product specific

pSivida Enters Licensing Negotiations with Major Global Pharma for ...  -  Dec 27, 2006
dBusinessNews Boston (press release),Bausch & Lomb own the trademarks Vitrasert® and Retisert™. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb.

pSivida enters licensing negotiations with major global pharma for ...  -  Dec 26, 2006
Nanovip.com (press release),Retisert™ is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis.

pSivida Signs Drug Delivery Licensing Agreement with Faber ...  -  Jan 9, 2007
PharmaLive.com (press release),...the company's ophthalmic drug delivery products, Retisert(TM), which is FDA approved, and Medidur(TM), which is currently in Phase III clinical trials.

pSivida Enters Licensing Negotiations with Major Global Pharma for ...  -  26 Dec 2006
PharmaLive.com (press release),Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). pSivida has licensed the technologies underlying both of these products to Bausch & Lomb.

Bausch & Lomb Reports Preliminary Third-Quarter and Year-to-Date ...  09 Nov 2006
Results also reflect incremental sales of Retisert TM drug delivery implants, partially offset by declines for general eye care products and certain non ... -Business Wire (press release), First Patient Implanted in pSivida European Pancreatic Cancer ...  Oct 9, 2006
...products. Retisert™ is FDA approved for the treatment of uveitis. ... Retinitis. Bausch & Lomb owns the trademarks Vitrasert® and Retisert™. ... -Business Wire (press release), Student ideas a hit with Disney  Oct 22, 2006
...into the eye. The new treatment is called Retisert and was just approved by the Food and Drug Administration. Foster, the founder ... -Boston Globe, pSivida: Retisert(TM) Wins International Award  Sep 13, 2006
Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that a paper describing the initial clinical work on its lead ophthalmology product Retisert(TM), has ... -Business Wire

Initiation of Phase II Clinical Study of Novel Ophthalmic Product  Sep 19, 2006
Retisert(TM) is the only FDA-approved sustained release back of the eye treatment for uveitis, a leading cause of blindness in the United States. ... -PharmaLive.com

pSivida wins recognition in Germany  Sep 12, 2006
...pSivida Ltd has won first prize in the field of Clinical Uveitis for a paper describing initial work on its lead ophthalmology product Retisert from the ... -WA Business News

pSivida Completes Agreement with Existing Convertible Note Holder  Sep 15, 2006
...products. Retisert(TM) is FDA approved for the treatment of uveitis. ... Retinitis. Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... -Genetic Engineering News

pSivida and Nordic Biotech Sign MOU for A$33.7M (US$26M) for ...  -  Nov 13, 2006
PharmaLive.com (press release),...pSivida's lead FDA approved ophthalmic product is Retisert(TM) for the treatment of uveitis, a leading cause of blindness in the United States. ...

pSivida Announces Transdermal Drug Delivery Program  -  Nov 20, 2006
PharmaLive.com (press release),...products. Retisert(TM) is FDA approved for the treatment of uveitis. ... Retinitis. Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ...

pSivida and Nordic Biotech Sign MOU for A$33.7M (US$26M) for ...  -  Nov 13, 2006
Nanotechnology.net (press release),...pSivida’s lead FDA approved ophthalmic product is Retisert™ for the treatment of uveitis. Medidur™ essentially differs from ...

pSivida and Nordic Biotech Sign Agreement for Funding and Equity ...  -  Nov 13, 2006
AZoNano.com,...pSivida's lead FDA approved ophthalmic product is Retisert for the treatment of uveitis, a leading cause of blindness in the United States. ...

Non-Exec Director Resigns from pSivida Board  Aug 28, 2006
...products. Retisert(TM) is FDA approved for the treatment of uveitis. ... Retinitis. Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... -Genetic Engineering News

Small implant gives hope to patients with eye disease  Jul 25, 2006
And, she may not have to. The new implant is called retisert. ... Studies show retisert helped decrease inflammation from uveitis and improve vision. ... -49abcnews.com

pSivida to Present at The NanoEquity Europe 2006 Conference  Jul 10, 2006
...products. Retisert(TM) is FDA approved for the treatment of uveitis. ... Retinitis. Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... -Genetic Engineering News

pSivida to Present at the Sachs Associates: London Biotech ...  Jun 22, 2006
...pSivida is a global bio-nanotech company committed to thebiomedical sector and the development of drug delivery products.Retisert(TM) is FDA approved for the ... -Finanzen.net

Psivida: A Biotech Platform With Great Potential (PSDV)  Jul 6, 2006
Vitrasert is a treatment for CMV Retinitis, while Retisert is an implant for chronic non-infectious Uvetis – a release for upto 20 months. ... -Seeking Alpha



PSIVIDA QUARTERLY CASHFLOW - MARCH 2006 COMMENTARY AND HIGHLIGHTS  May 1, 2006
...a review of costs being undertaken and implemented during the period and the receipt of payments from collaborative partners and Retisert(TM) royalties. ... - Small Times

pSivida Limited: Rights Issue to Fund Late Stage Macular Edema ...  May 2, 2006
...products. Retisert(TM) is FDA approved for the treatment of uveitis. ... Retinitis. Bausch & Lomb own the trademarks; Vitrasert(R) and Retisert(TM). ... - TMCnet

pSivida to Present at UBS Global Specialty Pharmaceuticals ...  Apr 21, 2006
...pSivida has developed the only two FDA approved sustained release back of the eye treatments for chronic eye disease - Retisert(TM) and Vitrasert(R). Both ... - TMCnet

pSivida to raise $29m to fund clinical trials  May 2, 2006
...to the back of the eye, we believe the Medidur™ trials in DME will show a very similar improvement in visual acuity to that shown in the Retisert™ DME trial ... - WA Business News





pSivida Release: Positive European trial results for Retisert(TM)  Apr 6, 2006
...announced that global eye health company Bausch & Lomb (NYSE:BOL) recently released two year results from their European clinical trial of Retisert(TM) for the ... - Genetic Engineering News

pSivida News: Retisert(TM) Slows Progression of Diabetic ...  Apr 3, 2006
PSI) today announced additional two year trial results of Bausch & Lomb's two randomized trials to evaluate the safety and efficacy of the Retisert(TM) implant ... - Genetic Engineering News

pSivida Signs New Evaluation Agreement for Cardiovascular Drug ...  Apr 5, 2006
Retisert(TM) and Vitrasert(TM) are the only FDA approved sustained release drug treatments to the back of the eye and both are licensed to Bausch & Lomb. ... - PharmaLive.com

pSivida Given a 'Speculative Buy Class A' Rating by Australian ...  Mar 28, 2006
The editors of Bioshares specifically focused on Retisert(TM) and Medidur(TM), implantable drug delivery systems for the back of the eye that can be used to ... - Genetic Engineering News

pSivida trials have positive results for diabetic eye disease  Apr 2, 2006
...pSivida receives royalties on Retisert™ sales. Retisert™ is presently priced at US$18,250 and. estimated 800,000 people worldwide. ... - WA Business News

pSivida Updates Shareholders on Status of Activities  Mar 22, 2006
Key points: -- Three year trial results from a Bausch & Lomb study on Retisert(TM) as a treatment for chronic non-infectious posterior segment uveitis, in ... - Genetic Engineering News

pSivida Updates Shareholders on Status of Activities  Mar 22, 2006
Three year trial results from a Bausch & Lomb study on Retisert as a treatment for chronic non-infectious posterior segment uveitis, in which a statistically ... - Nanotechwire.com

pSivida Given a 'Speculative Buy Class A' Rating by Australian ...  Mar 28, 2006
Overlaying this is a proven technology development team led by Paul Ashton.". The editors of Bioshares specifically focused on Retisert(TM) and Medidur(TM), ... - Therapeutics Daily (subscription)

pSivida Added to New Nanotechnology Index  Mar 17, 2006
Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved for the treatment of AIDS-related CMV Retinitis. ... - Genetic Engineering News

pSivida Announces Medidur(TM) Manufacture Certified to be GMP ...  Mar 20, 2006
...pSivida is a global bio-nanotech company committed to thebiomedical sector and the development of drug delivery products.Retisert(TM) is FDA approved for the ... - Finanzen.net



Bausch & Lomb, Novartis to co-promote Retisert eye drug in the US  Feb 9, 2006
ZURICH (AFX) - Bausch & Lomb said it and Novartis AG unit Novartis Ophtalmics are to co-promote eye drug Retisert in the United States. ... - Forbes

pSivida's Retisert to be co-promoted in the US  Feb 9, 2006
Shares in Western Australia's biggest biotechnology stock, pSivida Ltd, have risen 7 per cent following news that its Retisert product, licensed to Bausch & ... - WA Business News,

Diabetic Macular Edema trial with Retisert; Positive Results for ...  Feb 22, 2006
...the publication of preliminary three year follow-up data from Bausch and Lomb's multi-center, randomized, controlled clinical trial of Retisert for the ... - Nanotechwire.com,

Uveitis Long Term Trial Results Positive for pSivida; Second Set ...  Feb 21, 2006
PSI) today announced that preliminary three year follow-up data from Bausch and Lomb's multi-center, randomized, dose-masked clinical trial of Retisert(TM) for ... - Genetic Engineering News,

Bausch & Lomb Teams with Novartis Ophthalmics To Co-Promote Bausch ...  Feb 9, 2006
...(NYSE: NVS), willco-promote Bausch & Lomb's patented orphan drug Retisert(TM)(fluocinolone acetonide intravitreal implant) 0.59 mg, in the UnitedStates. ... - Finanzen.net,

Implant eases eye condition  Feb 5, 2006
The implant, called Retisert, delivers steroidal medication over two to three years and helps relieve inflammation. This method ... - Cherry Hill Courier Post,

Business briefs  Feb 11, 2006
Novartis Ophthalmics has agreed to help with US promotions for Bausch & Lomb Inc.'s Retisert, a drug that treats a sight-threatening disease called chronic non ... - Rochester Democrat and Chronicle,

Bausch & Lomb, Novartis to co-promote Retisert eye drug in the US  09 Feb 2006
ZURICH (AFX) - Bausch & Lomb said it and Novartis AG unit Novartis Ophtalmics are to co-promote eye drug Retisert in the United States. ... - Forbes

Bausch & Lomb Teams with Novartis Ophthalmics To Co-Promote Bausch ...  09 Feb 2006
...(NYSE: NVS), will co-promote Bausch & Lomb's patented orphan drug Retisert(TM) (fluocinolone acetonide intravitreal implant) 0.59 mg, in the United States. ... - Genetic Engineering News

Implant eases eye condition  Feb 5, 2006
The implant, called Retisert, delivers steroidal medication over two to three years and helps relieve inflammation. This method ... - Cherry Hill Courier Post

Eye Implant For Uveitis  Jan 26, 2006
Pills Or Shots.. But They Have Serious Side Effects. Now Doctors Are Using A New Implant Called Retisert. It's A Tiny Capsule Put Right In The Eye.. ... - CBS 5 - Green Bay

pSivida Names New Non-Executive Director; Australian Institutional ...  Jan 12, 2006
...pSivida owns or has the exclusive rights to use the intellectual property pertaining to BrachySil(TM), Medidur(TM), Retisert(TM) and Vitrasert(R). The ... - Business Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional